Capstone Therapeutics Q2 2025 Results: Gross Margin Jumps to 24.4%, First Acquisition Imminent

Reuters
08/15
Capstone <a href="https://laohu8.com/S/LENZ">Therapeutics</a> <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Results: Gross Margin Jumps to 24.4%, First Acquisition Imminent

Capstone Holding Corp. (NASDAQ: CAPS) has released its second quarter 2025 financial results, reporting a substantial increase in its gross margin, which rose to 24.4% from 21.4% in the same period the previous year. This improvement is attributed to increased sales of owned brands and disciplined cost management. The company is advancing its acquisition of a Carolina-based stone company, expected to close within the next 10 days. This acquisition is anticipated to be immediately accretive to revenue and EBITDA, expanding Capstone's presence in the high-growth Southeast market. Capstone is targeting a $100 million revenue run-rate by the end of 2025 or the first quarter of 2026, with additional acquisitions under review at attractive valuations. The company has secured flexible capital funding through an Equity Line of Credit and a convertible note, ensuring the availability of funds for future acquisitions without relying on high-interest debt. Looking ahead, Capstone expects a rebound in Q3 order volumes as market conditions stabilize, with potential interest rate cuts in late 2025 providing additional demand support. The company continues to focus on product rollouts and expanding into new territories to maintain momentum.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1061481) on August 15, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10